1
|
International Agency for Research on
Cancer: The GLOBOCAN project: cancer incidence and mortality
worldwide in. 2013.http://globocan.iarc.frAccessed. February
21–2014
|
2
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
3
|
Rini BI, Escudier B, Tomczak P, Kaprin A,
Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME,
Rusakov IG, et al: Comparative effectiveness of axitinib versus
sorafenib in advanced renal cell carcinoma (AXIS): A randomised
phase 3 trial. Lancet. 378:1931–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Eisen T, Sternberg CN, Robert C, Mulders
P, Pyle L, Zbinden S, Izzedine H and Escudier B: Targeted therapies
for renal cell carcinoma: review of adverse event management
strategies. J Natl Cancer Inst. 104:93–113. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Rini BI: Metastatic renal cell carcinoma:
Many treatment options, one patient. J Clin Oncol. 27:3225–3234.
2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Gore ME, Szczylik C, Porta C, Bracarda S,
Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano
D, et al: Safety and efficacy of sunitinib for metastatic
renal-cell carcinoma: An expanded-access trial. Lancet Oncol.
10:757–763. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hudes G, Carducci M, Tomczak P, Dutcher J,
Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi
I, et al: Global ARCC Trial: Temsirolimus, interferon alfa, or both
for advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281.
2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Gomez-Fernandez C, Garden BC, Wu S,
Feldman DR and Lacouture ME: The risk of skin rash and stomatitis
with the mammalian target of rapamycin inhibitor temsirolimus: A
systematic review of the literature and meta-analysis. Eur J
Cancer. 48:340–346. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Fujihara S, Mori H, Kobara H, Suenaga T,
Hayashida Y, Sugimoto M, Kakehi Y and Masaki T: Life-threatening
gastrointestinal bleeding during targeted therapy for advanced
renal cell carcinoma: A case report. BMC Nephrol. 14:1412013.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Je Y, Schutz FA and Choueiri TK: Risk of
bleeding with vascular endothelial growth factor receptor
tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic
review and meta-analysis of clinical trials. Lancet Oncol.
10:967–974. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kamba T and McDonald DM: Mechanisms of
adverse effects of anti-VEGF therapy for cancer. Br J Cancer.
96:1788–1795. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Schmelzle T and Hall MN: TOR, a central
controller of cell growth. Cell. 103:253–262. 2000. View Article : Google Scholar : PubMed/NCBI
|
13
|
Fingar DC, Richardson CJ, Tee AR, Cheatham
L, Tsou C and Blenis J: mTOR controls cell cycle progression
through its cell growth effectors S6K1 and 4E-BP1/eukaryotic
translation initiation factor 4E. Mol Cell Biol. 24:200–216. 2004.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Kirkali Z: Adverse events from targeted
therapies in advanced renal cell carcinoma: The impact on long-term
use. BJU Int. 107:1722–1732. 2011. View Article : Google Scholar : PubMed/NCBI
|